Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01852201 · ClinicalTrials.gov registry record · NA
POSITIVE Stroke Clinical Trial
A NA study, sponsored by Medical University of South Carolina.
- Terminated
- Registry status
- NA
- Development phase
- 33
- Enrollment target
NCT01852201: Clinical Trial NA study, sponsored by Medical University of South Carolina.
NCT01852201 is a NA study that was terminated before completion, run by Medical University of South Carolina. The registered enrollment target is 33 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01852201, a NA study, was terminated before completion, sponsored by Medical University of South Carolina.
- TERMINATED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
Study Summary
Primary Endpoint: The primary objective is to show that AIS patients, ineligible for or refractory to treatment with IV-tPA, with appropriate image selection, treated with mechanical thrombectomy within 6-12 hours of symptom onset have less stroke related disability and improved good functional outcomes as compared to those treated with best MT with respect to endpoint defined as: • 90-day global disability assessed via the modified Rankin score (mRS), analyzed using raw mRS scores. Statistical details can be found in section 7.2. Secondary Endpoints: * 90-day global disability in the 6-12 hr cohort assessed via the overall distribution of mRS * Proportion of patients with good functional recovery for the 6-12 hr cohort as defined by mRS 0-2 at 90 days * Mortality at 30 and 90 days * Intracranial hemorrhage with neurological deterioration (NIHSS worsening \>4) within 24 hours of randomization * Procedure related serious adverse events (SAE's) * Arterial revascularization measured by TICI 2b or 3 following device use
Primary Outcome
Modified rankin score measures the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The range is 0-6 (0 is highest function with no symptoms and 6 is death). This outcome measured percentage of subjects with a "good" functional outcome with a score ranging from 0-2. The primary objective is to show that AIS patients, ineligible for or refractory to treatment with IV-tPA, (patients seen within 6 hours of s
Interventions
- DEVICE Endovascular Mechanical Thrombectomy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2013-09 |
| Est. Completion | 2017-05-31 |
| Phase | NA |
Why NCT01852201 stopped before completion
NCT01852201 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Endovascular Mechanical Thrombectomy is the first listed.
NCT01852201 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01852201 about?
NCT01852201 is a clinical study titled "POSITIVE Stroke Clinical Trial". Primary Endpoint: The primary objective is to show that AIS patients, ineligible for or refractory to treatment with IV-tPA, with appropriate image selection, treated with mechanical thrombectomy within 6-12 hours of symptom onset have less stroke related disability and improved good functional out...
What is the current status of trial NCT01852201?
This trial is currently terminated. It is a NA study. The enrollment target is 33 participants. The study started on 2013-09. Estimated completion is 2017-05-31.
What interventions are being tested in trial NCT01852201?
The interventions under investigation include: Endovascular Mechanical Thrombectomy (DEVICE).
Who is sponsoring clinical trial NCT01852201?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01852201's enrollment target sits among peer trials
33 1574th of 2000 higher than 423 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia